AQST · Aquestive Therapeutics, Inc.
$5.16
-0.23 (-4.27%)
At close · Aug 27
Market Cap
$676.51M
Shares
125.51M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$44.55M
-22.6%
FY2025
Net Income
-$83.78M
-89.8%
FY2025
Gross Margin
58.35%
-10.6pp
FY2025
Operating Margin
-159.5%
-106pp
FY2025
Diluted EPS
-$0.78
-52.9%
FY2025
Operating Cash Flow
-$52.43M
-46.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $46M – $50M | $54.09M | $44.55MG | $57.56MG | $50.58MG | $47.68MG | $50.83M | $45.85M | $52.61M | $67.43M | $66.92M | |
| — | $17.83M | $18.56M | $17.87M | $20.83M | $19.39M | — | $12.96M | $20.36M | — | — | |
| — | $36.26M | $25.99M | $39.69M | $29.75M | $28.29M | — | $32.89M | $32.25M | — | — | |
| — | — | 58.35% | 68.95% | 58.82% | 59.34% | — | 71.72% | 61.3% | — | — | |
| — | $15.89M | $17.19M | $20.28M | $13.1M | $17.48M | $17.05M | $19.89M | $20.57M | $23.11M | $22.13M | |
| — | $73.11M | $79.85M | $50.18M | $31.75M | $52.88M | $53.48M | $55.89M | $64.34M | $72.27M | $25.08M | |
| — | — | $0 | $78K | $157K | $116K | $51K | $51K | $50K | $50K | $51K | |
| — | — | $548K | $718K | $1.35M | $2.39M | $2.96M | $3.44M | $2.91M | $3.19M | $3.75M | |
| — | — | — | — | — | $89.75M | $85.51M | $88.74M | $105.28M | $116.37M | $67.03M | |
| — | $106.83M | $115.6M | $88.33M | $65.69M | $89.75M | — | $88.74M | $105.28M | — | — | |
| — | -$52.75M | -$71.05M | -$30.77M | -$15.1M | -$42.07M | -$34.68M | -$42.89M | -$52.67M | -$48.93M | -$113K | |
| — | — | -159.5% | -53.46% | -29.86% | -88.23% | -68.22% | -93.55% | -100.11% | -72.57% | -0.17% | |
| — | — | -$70.5M | -$30.05M | -$13.76M | -$39.68M | -$31.72M | -$39.45M | -$49.76M | -$45.75M | $3.64M | |
| — | $11.27M | $11.12M | $11.12M | $6.34M | $6.55M | $10.05M | $11.06M | $9.32M | $7.71M | $7.71M | |
| — | — | — | — | — | — | — | $132K | $636K | — | — | |
| — | -$78.23M | -$83.78M | -$44.15M | -$7.63M | -$54.41M | -$70.54M | -$55.78M | -$66.25M | -$61.38M | -$8.94M | |
| — | $0 | $0 | -$14K | $245K | $0 | $0 | $0 | $0 | $0 | $0 | |
| — | -$78.23M | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M | -$55.78M | -$66.25M | -$61.38M | -$8.94M | |
| — | — | -188.09% | -76.68% | -15.56% | -114.11% | -138.77% | -121.67% | -125.92% | -91.02% | -13.36% | |
| — | — | — | — | — | — | — | — | — | -$61.38M | -$11.42M | |
| — | -$78.23M | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M | -$55.78M | -$66.25M | -$61.38M | -$11.42M | |
| USD/shares | — | -$0.65 | -$0.78 | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 | — | — | — |
| USD/shares | — | -$0.65 | -$0.78 | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 | — | — | — |
| shares | — | — | 106.93M | 86.73M | 61.26M | 48.73M | 38.08M | 33.65M | 25.36M | 20.73M | — |
| shares | — | — | 106.93M | 86.73M | 61.26M | 48.73M | 38.08M | 33.65M | 25.36M | 20.73M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
11.62×
Peer median 1.97×
EV/EBIT
—
Peer median 15.16×
P/E (TTM)
—
Peer median 14.61×
Peer medians compare against the 49 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $44,545,000 | $57,561,000 | $50,583,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $29,604,000 | $39,930,000 | $37,104,000 | $40,792,000 | $42,860,000 | $40,956,000 |
| Non Us | $14,941,000 | $17,631,000 | $13,479,000 | $6,888,000 | $7,972,000 | $4,893,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Manufacture and Supply Revenue | $40,225,000 | $39,976,000 | $43,805,000 | $36,378,000 | $35,312,000 | $24,881,000 |
| License and Royalty Revenue | $3,519,000 | $15,345,000 | $5,376,000 | $2,351,000 | $5,380,000 | $14,055,000 |
| Co Development and Research Fees | $1,279,000 | $1,925,000 | $1,402,000 | $1,293,000 | $1,635,000 | $1,264,000 |
| Royalty | $938,000 | $1,008,000 | $989,000 | — | — | — |
| Proprietary Product Revenue | -$478,000 | $315,000 | $0 | — | — | — |
| Proprietary Product Sales | — | — | $0 | $7,658,000 | $8,505,000 | $5,649,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$71,051,000 | -$30,771,000 | -$15,102,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -159.5% | -53.5% | -29.9% |
Key facts
CIK
1398733
CUSIP
03843E104
13F (30d)
161 filings
159 filers
Visit website
Investor relations